Eulav Asset Management Dexcom Inc Transaction History

Eulav Asset Management

$4.11 Billion
Q3 2024

A detailed history of Eulav Asset Management transactions in Dexcom Inc stock. As of the latest transaction made, Eulav Asset Management holds 81,000 shares of DXCM stock, worth $6.14 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

81,000

Previous 75,014 7.98%

Holding current value

$6.14 Million

Previous $8.51 Million 36.18%

% of portfolio

0.13%

Previous 0.23%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$64.0 - $116.06 $383,104 - $694,735	5,986 Added 7.98%	81,000 $5.43 Million
Q2 2024 Aug 13, 2024	SELL	$110.31 - $140.45 $1.54 Million - $1.97 Million	-13,999 Reduced 15.73%	75,014 $8.51 Million
Q1 2024 May 30, 2024	SELL	$114.22 - $140.1 $1.03 Million - $1.26 Million	-8,987 Reduced 9.17%	89,013 $12.3 Million
Q4 2023 Feb 14, 2024	SELL	$75.49 - $124.16 $150,980 - $248,320	-2,000 Reduced 2.0%	98,000 $12.2 Million
Q3 2023 Nov 13, 2023	BUY	$86.06 - $137.93 $1.89 Million - $3.03 Million	21,938 Added 28.1%	100,000 $9.33 Million
Q2 2023 Aug 09, 2023	SELL	$112.47 - $130.98 $1.23 Million - $1.43 Million	-10,938 Reduced 12.29%	78,062 $10 Million
Q1 2023 Apr 27, 2023	BUY	$104.0 - $122.92 $312,000 - $368,760	3,000 Added 3.49%	89,000 $10.3 Million
Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $3.06 Million - $4.42 Million	-36,000 Reduced 29.51%	86,000 $9.74 Million
Q3 2022 Nov 03, 2022	BUY	$76.35 - $94.18 $763,500 - $941,800	10,000 Added 8.93%	122,000 $9.83 Million
Q2 2022 Jul 22, 2022	BUY	$67.99 - $132.89 $6.32 Million - $12.4 Million	93,000 Added 489.47%	112,000 $8.35 Million
Q1 2022 May 10, 2022	SELL	$94.08 - $130.2 $564,480 - $781,199	-6,000 Reduced 24.0%	19,000 $9.72 Million
Q4 2021 Feb 11, 2022	SELL	$129.87 - $162.82 $1.82 Million - $2.28 Million	-14,000 Reduced 35.9%	25,000 $13.4 Million
Q3 2021 Nov 15, 2021	SELL	$106.71 - $143.18 $1.28 Million - $1.72 Million	-12,000 Reduced 23.53%	39,000 $21.3 Million
Q2 2021 Aug 06, 2021	BUY	$80.99 - $107.93 $809,900 - $1.08 Million	10,000 Added 24.39%	51,000 $21.8 Million
Q4 2020 Feb 16, 2021	BUY	$78.0 - $104.5 $312,000 - $418,000	4,000 Added 10.81%	41,000 $15.2 Million
Q3 2020 Nov 05, 2020	SELL	$95.51 - $112.95 $47,755 - $56,475	-500 Reduced 1.33%	37,000 $15.3 Million
Q2 2020 Aug 11, 2020	SELL	$62.68 - $105.34 $814,840 - $1.37 Million	-13,000 Reduced 25.74%	37,500 $15.2 Million
Q1 2020 Apr 27, 2020	SELL	$47.79 - $75.63 $645,165 - $1.02 Million	-13,500 Reduced 21.09%	50,500 $13.6 Million
Q4 2019 Feb 13, 2020	SELL	$36.62 - $57.29 $329,580 - $515,610	-9,000 Reduced 12.33%	64,000 $14 Million
Q3 2019 Nov 12, 2019	SELL	$35.53 - $43.8 $1.1 Million - $1.36 Million	-31,000 Reduced 29.81%	73,000 $10.9 Million
Q2 2019 Aug 05, 2019	BUY	$27.84 - $38.92 $1.06 Million - $1.48 Million	38,000 Added 57.58%	104,000 $15.6 Million
Q4 2018 Feb 14, 2019	SELL	$26.99 - $37.37 $242,910 - $336,330	-9,000 Reduced 12.0%	66,000 $7.91 Million
Q3 2018 Oct 26, 2018	SELL	$23.35 - $36.72 $116,750 - $183,600	-5,000 Reduced 6.25%	75,000 $10.7 Million
Q2 2018 Aug 14, 2018	SELL	$17.54 - $25.22 $17,540 - $25,220	-1,000 Reduced 1.23%	80,000 $7.6 Million
Q1 2018 May 09, 2018	SELL	$13.06 - $18.54 $274,260 - $389,340	-21,000 Reduced 20.59%	81,000 $6.01 Million
Q4 2017 Feb 14, 2018	SELL	$11.12 - $15.38 $88,960 - $123,040	-8,000 Reduced 7.27%	102,000 $5.85 Million
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $227,200 - $379,600	20,000 Added 22.22%	110,000 $5.38 Million
Q2 2017 Aug 14, 2017	BUY	N/A	90,000	90,000 $6.58 Million

Others Institutions Holding DXCM

# of Institutions

1,014

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.3B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eulav Asset Management with notifications on news.

Account

Eulav Asset Management Dexcom Inc Transaction History